As a primary approach in treating glioblastomas, radiotherapy can upregulate the expression of monocyte chemokine-1 (MCP-1)/C-C basal chemokine ligand 2 (CCL-2) in the tumor region, promoting the chemotaxis of monocytes [117]. Here, CCL2 is linked to neoplasm.